Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HELP
HELP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HELP News
Helus Pharma Welcomes White House Executive Order on Psychedelic Treatments
1d ago
Newsfilter
Trump Signs Executive Order to Accelerate Psychedelic Research
1d ago
CNBC
White House Psychedelics Executive Order Accelerates Research
1d ago
Newsfilter
Helus Pharma CEO Michael Colais Steps Down Immediately
1d ago
seekingalpha
Helus Pharma Announces Transition in Leadership; Eric So to Take on Interim CEO Role
1d ago
moomoo
Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews
1d ago
Newsfilter
Trump Administration to Examine Safety of Psychedelic Drug for PTSD
3d ago
Yahoo Finance
Helus Pharma Appoints New SVP of Medical Affairs
5d ago
Newsfilter
Helus Pharma Advances New Drug for Anxiety Treatment
Mar 09 2026
Newsfilter
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
Mar 09 2026
PRnewswire
Helus Pharma's Anxiety Drug Trial Results Trigger Stock Plunge
Mar 06 2026
stocktwits
US Stock Futures Stabilize Amid Oil Price Surge
Mar 06 2026
stocktwits
Helus Pharma's HLP004 Phase 2 Study Results Disappoint
Mar 05 2026
Benzinga
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
Mar 05 2026
PRnewswire
GAD Therapies Market Expected to Reach $4.26B by 2033 Amid Rising Demand
Mar 05 2026
Newsfilter
Helus Pharma Reports Significant Phase 2 Trial Results for Anxiety Disorder Therapy
Mar 05 2026
seekingalpha
Show More News
